NCT00582582终止2 期
Phase II Evaluation of Docetaxel Randomized With Doxercalciferol or Placebo in Patients With Advanced Prostate Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 70
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
The purpose of this research study is to find out the toxicities of doxercalciferol given in combination with docetaxel (Taxotere®), as well as to see how well this combination works in the treatment of prostate cancer.
详细描述
This is a multi-institutional, double-blinded, randomized study comparing docetaxel plus doxercalciferol versus docetaxel plus placebo in patients with metastatic hormone refractory prostate cancer. Docetaxel is given intravenously on days 1, 8 and 15 for every 28 day cycle and doxercalciferol or placebo is taken orally every day of the 28 day cycle. Please refer to the Eligibility Criteria below for key inclusion and exclusion criteria.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of adenocarcinoma of the prostate.
- •evidence of metastatic disease within 4 weeks of registration.
- •Must meet ONE of the following:
- •PSA >or= 10 ng/mL and at least one lesion on bone scan.
- •Soft tissue metastases and/or visceral disease per CT scan.
- •Must show progressing prostate cancer as seen by one of the following:
- •At least one new lesion on bone scan,
- •Increase in size or number of measurable disease lesions,
- •At least 2 rising PSA measurements at least two weeks apart.
- •Prior bilateral orchiectomy or on LHRH agonist therapy with a serum testosterone level of <
- •Must be off flutamide, nilutamide, or ketoconazole or herbal supplements used to treat prostate cancer at least 4 weeks prior to registration and bicalutamide at least 6 weeks prior to registration.
- •No prior cytotoxic chemotherapy.
- •WHO performance status of 0-
- •Peripheral neuropathy must be < or = to grade 1.
排除标准
- •A history of a radiographically confirmed kidney stone or pathologically confirmed calcium stone within the last 10 years.
- •Patients can continue to take bisphosphonates during the study as long as the bisphosphonate was started at least 4 weeks prior to study entry and the patient continues to demonstrate a rising PSA
- •No prior treatment with suramin, strontium or other therapeutic radioisotopes.
- •No radiotherapy within the past 4 weeks.
- •No known brain metastases.
- •No chronic hypercalcemia (serum calcium >1.0 mg/dl above the upper limit of normal range), chronic gastrointestinal disease (malabsorption, surgery affecting absorption, chronic ulcerative colitis) or any condition that the investigator feels would put the patient at undue risk.
- •Must not be taking digitalis, thiazide diuretics (or drugs in combination with thiazides) or calcium supplements within one week of treatment initiation.
- •No active angina, known heart disease of New York Heart Association Class II-IV or a recent history (< 6 months) of myocardial infarction.
- •Must not be taking steroids, anticonvulsants, fluoride, or lithium.
- •Must not have urinary protein > 4gm/24 hours
- •Must not have urinary calcium > or= 500 mg/24 hours
- •No Coexistent second malignancy or history of prior malignancy within previous 5 years (excluding basal or squamous cell carcinoma of the skin that has been treated curatively).
研究组 & 干预措施
A
Experimental
Docetaxel plus doxercalciferol
干预措施: Docetaxel plus doxercalciferol (Drug)
B
Placebo Comparator
Docetaxel plus placebo
干预措施: Docetaxel plus placebo (Drug)
结局指标
主要结局
Objective response rate
时间窗: At 12 weeks on study
次要结局
- Safety(Duration of study participation through 30 days post last treatment dose)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid TumorsSolid TumorsNon-small Cell Lung CancerGastric CancerBreast CancerProstate CancerNCT01803503National University Hospital, Singapore80
已完成
2 期
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck CancerHead and Neck CancerNCT00148122University of Michigan Rogel Cancer Center40
已完成
2 期
A Study of Docetaxel Plus Carboplatin in Patients With Hormone Refractory Prostate CancerProstate CancerNCT00134706Dana-Farber Cancer Institute30
Unknown
2 期
Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before SurgeryBreast CancerNCT00251329Cancer Research Network48
终止
3 期
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaCarcinoma, Non-small Cell LungNCT02775006The Netherlands Cancer Institute45